Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Transaction worth based connected SEC Form 4 reported terms ($21.64); post-transaction worth based connected April 2, 2026 marketplace adjacent ($21.84). Gift shares: 6,291 shares talented connected March 30, 2026 are excluded from each stock counts, transaction values, and post-transaction balances above.

• How did this transaction interaction Higgins’s wide ownership successful Immunome?
  The merchantability reduced Higgins's nonstop holdings by 30.02%, from 31,438 to 22,000 shares.

• Was the full disposition executed directly, oregon were indirect holdings besides affected?
  The full 9,438-share merchantability was executed from nonstop holdings; indirect shares attributed to his children’s custodial accounts were unaffected and stay astatine 3,000 shares.

• What is the rationale oregon discourse for the timing and method of this sale?
  The merchantability was executed nether a pre-arranged Rule 10b5-1 trading plan, supporting the presumption that this was regular liquidity absorption alternatively than discretionary marketplace timing.

• How does this transaction subordinate to Higgins’s humanities trading activity?
  One anterior open-market merchantability appears successful the disposable EDGAR filing past — 3,524 shares sold connected August 15, 2024. At 9,438 shares, this transaction is astir 2.7 times larger than that anterior sale.

* 1-year terms alteration calculated utilizing April 2, 2026 arsenic the notation date.

• Immunome develops antibody therapeutics targeting oncology and infectious diseases, with pb programs including IMM-ONC-01 for crab and IMM-BCP-01 for SARS-CoV-2.

• The institution operates a research-driven concern exemplary focused connected discovering and advancing proprietary antibody-based therapies.

• Immunome targets pharmaceutical companies, healthcare providers, and patients successful the oncology and infectious illness markets.

Immunome is simply a clinical-stage biotechnology institution specializing successful the find and improvement of antibody therapeutics for crab and infectious diseases. The company's strategy leverages proprietary platforms to code unmet aesculapian needs done caller immune-based therapies. Its competitory borderline lies successful advancing differentiated antibody programs with the imaginable for first-in-class oregon best-in-class profiles.